Key result
Rheumatic diseases and their therapies compound cardiovascular mortality and complication risks in women.
Why the study?
Women with rheumatic diseases are exceptionally vulnerable to cardiovascular disease, but the underlying mechanisms and optimal management strategies remain incompletely understood.
This review highlights the critical need for a cardio-rheumatology subspecialty to manage the compounded cardiovascular and pharmacological risks in women with rheumatic diseases.
Answers are grounded in this paper and cite their sources.
Supports integrated cardio-rheumatology care models for women with rheumatic diseases; leaves open prospective trials to define optimal strategies.
Cardiovascular disease (CVD) remains the number one cause of death worldwide. Women are at increased risk of death from CVD, but the mechanisms for how and why this occurs remain elusive. One subset of women who are exceptionally vulnerable to CVD are those with rheumatic diseases (RDs). Indeed, women account for 80% of all RDs, disorders that encompass a broad range of autoimmune and autoinflammatory diseases that lead to chronic inflammation and pathology. The clear association of increased CVD risk in women with RD is thought to be mediated by a number of factors, including RD pathology itself, pharmacological induction of CVD, and/or as yet unidentified mechanisms. As such, elucidation of the causes and treatments of these pathologies has given rise to a new subspecialty of cardiology: cardio-rheumatology. Here, we review and discuss the CVD risks in patients with RDs, the associated sex disparities in RD and CVD care, as well as the current therapeutic and interventional options available to specifically help women with RDs. We hope this discussion will provide guidance and support to patients, as well as to cardio-rheumatologists, as these groups are the most uniquely positioned to radically improve CVD care in these individuals. Moreover, we are hopeful this discussion may lead to better, more efficacious approaches to treating these disorders in women in the near future.
No takes yet. Share an insight, caveat, or question.
Sommer et al. (2024) conducted a review in Rheumatic diseases and cardiovascular disease in women. Rheumatic diseases was evaluated. Women with rheumatic diseases face a compounded increased risk of cardiovascular mortality and complications due to the disease itself and its pharmacological treatments.
Synapse has enriched 10 related papers. Consider them for comparative context: